Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States
Brogan, A., Talbird, S., Thompson, JR., Kim, YA., Olson, J., Peterson, J., Piontkowsky, D., & Pietrandoni, G. (2013). Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States. Value in Health, 16(7), A343-A344.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.